IMRA (near 52-week low with potential to gap fill)

Took a massive dip upon failing FDA approval but still a solid company. Dipped to about 13.7 as of 01/25/2021 and looking for it to fill the gap at around 15. Could potentially make a steady climb and pop if FDA approval does succeed once again.